Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 1.00 |
| ▸ | P2RY2 | P41231 | 3/20 | 1.00 |
| ▸ | P2RX1 | P51575 | 3/20 | 1.00 |
| ▸ | P2RX3 | P56373 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 1.00 |
| ▸ | P2RX4 | Q99571 | 1/20 | 1.00 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.93 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.93 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.93 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.93 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.85 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.85 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.85 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.85 |
| ▸ | LDHA | P00338 | 1/20 | 0.85 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.85 |
| ▸ | FBP1 | P09467 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diadenosine Tetraphosphate SCHEMBL849869 | 1.00 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL1744586 | 1.00 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL4357990 | 1.00 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Diadenosine Tetraphosphate SCHEMBL4069414 | 1.00 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL6516963 | 1.00 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Diadenosine Tetraphosphate SCHEMBL14205963 | 1.00 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL2934890 | 1.00 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Diadenosine Tetraphosphate SCHEMBL4363130 | 1.00 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Diadenosine Tetraphosphate SCHEMBL10069136 | 1.00 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL21067711 | 1.00 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | claimed |
| EP-4658261-A1 | METHODS FOR ACTIVATING IMMUNE CELLS TO KILL BACTERIA | The Texas A&M University System (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250049894-A1 | TREATMENT OF NUDT2 MUTATION | UNIV GENEVE (CH) | 2025-02-13 | — | — | US | claimed |
| WO-2024163692-A1 | METHODS FOR ACTIVATING IMMUNE CELLS TO KILL BACTERIA | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-08-08 | — | — | WO | claimed |
| EP-4408431-A1 | TREATMENT OF NUDT2 MUTATION | Université de Genève (CH) | 2024-08-07 | — | — | EP | claimed |
| EP-4389214-A2 | USE OF TRIMETHOXYBENZYL ACETYLSINAPATE, ADVANTAGEOUSLY IN COMBINATION WITH AT LEAST ONE SUNSCREEN, FOR PROTECTING THE SKIN | Thorel, Jean-Noël (FR) | 2024-06-26 | — | — | EP | claimed |
| EP-3466419-B1 | USE OF TRIMETHOXYBENZYL ACETYLSINAPATE, ADVANTAGEOUSLY IN COMBINATION WITH AT LEAST ONE SUNSCREEN, FOR PROTECTING THE SKIN | THOREL JEAN NOEL (FR) | 2024-05-08 | — | — | EP | claimed |
| US-20230302031-A1 | Modulators Of Purinergic Receptors and Related Immune Checkpoint For Treating Acute Respiratory Distress Syndrome | INSTITUT GUSTAVE-ROUSSY (FR) | 2023-09-28 | — | — | US | claimed |
| EP-4240339-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | Fred Hutchinson Cancer Center (US) | 2023-09-13 | — | — | EP | claimed |
| US-20230263800-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | FRED HUTCHINSON CANCER CENTER (US) | 2023-08-24 | — | — | US | claimed |
| WO-2023052411-A1 | TREATMENT OF NUDT2 MUTATION | UNIVERSITÉ DE GENÈVE (CH) | 2023-04-06 | — | — | WO | claimed |
| EP-4157288-A2 | MODULATORS OF PURINERGIC RECEPTORS AND RELATED IMMUNE CHECKPOINT FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROM | Institut Gustave-Roussy (FR) | 2023-04-05 | — | — | EP | claimed |
| US-11376272-B2 | Methods of modulating immune activity | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-07-05 | — | — | US | claimed |
| WO-2022098776-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-05-12 | — | — | WO | claimed |
| US-20260136663-A1 | SEMICONDUCTOR DEVICES | SAMSUNG ELECTRONICS CO LTD (KR) | 2026-05-14 | — | — | US | disclosed |
| CN-122028500-A | Semiconductor device with a semiconductor device having a plurality of semiconductor chips | 三星电子株式会社 | 2026-05-12 | — | — | CN | disclosed |
| WO-2026090438-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | DIRECT BIOLOGICS, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2022023582-A1 | METHODS FOR SCREENING COMPOUNDS FOR BACTERICIDAL ACTIVITY AND FOR DETERMINING THE SENSITIVITY OF BACTERIAL SAMPLES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-02-03 | — | — | WO | disclosed |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| WO-2022018347-A1 | AQUEOUS COMPOSITION HAVING TROPHIC PROPERTIES WITH RESPECT TO SKIN CELLS AND CAPABLE OF FACILITATING THE FORMULATION OF COSMETIC OR VETERINARY PRODUCTS | NAOS INSTITUTE OF LIFE SCIENCE (FR) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | STING1, IRF3, CGAS | P2RY1 9/4885P2RY2 8/4885P2RX1 10/4885 |
| US-20260136663-A1 | SEMICONDUCTOR DEVICES | NOTCH4, CD47, EPCAM | P2RY1 2386/4885P2RY2 1668/4885P2RX1 1560/4885 |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LIPA, HDLBP, PLTP | P2RY1 4489/4885P2RY2 4401/4885P2RX1 4604/4885 |
| US-20230263800-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | BMP4, P2RY2, GPR39 | P2RY1 6/4885P2RY2 2/4885P2RX1 17/4885 |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | EPB41L2, MYLK2, RABL3 | P2RY1 4152/4885P2RY2 3588/4885P2RX1 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.